Dear patients,
dear colleagues,
dear visitors,
dear Students,
We are pleased that you are interested in our clinic, which, as one of the largest neurological clinics in northern Germany, is available to you with the best possible treatment and a high level of expertise in research and teaching.
Our treatment, which is based on the latest standards of care and the latest results of clinical and basic research, covers the entire spectrum of neurological diseases with nationally and internationally recognized expertise in the areas of movement disorders, dementia, pain, stroke/vascular diseases, epilepsy, neuroimmunology and neurogeriatrics. In addition, the training of students and doctors as well as the constant research into ever better diagnostic and therapeutic options are very important to us.
We cordially invite you to get to know our clinic on the following pages and during a personal visit to the Neuro Center on the premises of the Schleswig-Holstein University Clinic in Kiel.
We look forward to being able to assist you with our expertise and care.
Best regards, Prof. Dr. Daniela Berg
Klinik für Neurologie
director of the clinic
Chairman and head of the Department of Neurology
University Clinic of Schleswig-Holstein,
Campus Kiel Arnold-Heller-Straße 3,
Haus 41
24105 Kiel
Tel.: 0431/597 8500
Fax: 0431/597 8502
E‑mail: daniela.berg@uksh.de
Medical qualifications
- State examination in Medicine, Würzburg 1994
- Board-examined neurologist
- Training authorization for neurology
Areas of clinical Expertise
- Diagnosis and therapy of Parkinson’s disease
- Early diagnosis of Parkinson’s disease and dementia
- Movement disorders
- Stroke
- General Neurology
- Neuro-Rehabilitation
Academic Qualifications
- Thesis, Würzburg, 1996
- Post Doc in Genetics, Tübingen 2002–2003
- Habilitation for Neurology, Tübingen, 2004
- Associate Professor for Neurology, Tübingen 2007
- Full Professor for Neurology, Christian-Albrechts-University of Kiel,2016
Research Interests
- Early diagnosis of Parkinson’s disease and Dementia
- Biomarker for early diagnosis and progression of neurodegenerative diseases
- Clinical studies, individualized therapy
- B‑mode sonography of the brain
- Learning – plasticity of the brain
Memberships
- Deutsche Gesellschaft für Neurologie (DGN), Deutsche Parkinson Gesellschaft, Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM), Deutsche Gesellschaft für Neurogenetik (DGNG), Movement Disorder Society (MDS), Neurotoxicity Society, European Society of Neurosonology and Cerebral Hemodynamics (ESNCH)
Activities in research Societies
- Editorial board member of several national and international journals
- Reviewer of numerous national and international research funding programs
- Reviewer for > 30 scientific journals
- Board member of the German Society for Parkinson’s disease since 2011 (President 2013–2015)
- Board member of the International Executive Committee of the Movements Disorders Society since 2015
- Board member of Parkinson’s UK Research Strategy Board since 2014
- Chair of the Task Force “Definition of Parkinson’s Disease” of the Movement Disorder Society 2011 – 2015
- Board member of Scientific advisory board of the German Parkinson Association since 2010
- Board member of the executive committee for the “S3-Leitlinien” for Parkinson’s disease
Awards
- Parkinson-Award of the German Society for Neurology (DGN), 1999
- Dissertation award of the “Unterfränkischen Gedenkjahrstiftung“ for Science, 2002
- Parkinson’s Research Award of the Hilde-Ulrichs-Foundation (Genetics of iron metabolism), 2004
- Dingebauer-Award of the German Society for Neurology (DGN), 2014
- Best Review Award der Movement Disorders Society, 2015
Grants
- BMBF, European Union, Michael-Fox Foundation, private foundations, Research cooperations with the industry,
- head of national and international clinical studies
Ten selected Publications
- Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1600–11
- Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1591–601
- Maetzler W, Pilotto A, Apel A, Deuschle C, Kuebart G, Heinzel S, Liepelt-Scarfone I, Schulte C, Reusch D, Schleicher E, Rothfuss O, Schneider A, Dodel R, Gasser T, Berg D. In vivo markers of Parkinson’s disease and dementia with Lewy bodies: current value of the 5G4 α‑synuclein antibody. Acta Neuropathol. 2014 Dec;128(6):893–5
- Reinhardt P, Schmid B, Burbulla LF, Schöndorf DC, Wagner L, Glatza M, Höing S, Hargus G, Heck SA, Dhingra A, Wu G, Müller S, Brockmann K, Kluba T, Maisel M, Krüger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, Müller H, Gasser T, Schöler HR, Sterneckert J.Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression. Cell Stem Cell. 2013 Mar 7;12(3):354–67
- Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, Liepelt-Scarfone I, Pausch C, Schneider N, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Gasser T, Poewe W. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson’s disease. Mov Disord. 2013 Feb;28(2):216–9
- Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, Schulte C, Mustafa S, Synofzik M, Vukovic Z, Itohara S, Berg D, Teismann P. S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF‑α pathway. Brain. 2012 Nov;135(Pt 11):3336–47
- Brockmann K, Hilker R, Pilatus U, Baudrexel S, Srulijes K, Magerkurth J, Hauser AK, Schulte C, Csoti I, Merten CD, Gasser T, Berg D, Hattingen E. GBA-associated PD: Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology. 2012 Jul 17;79(3):213–20.
- Berg D, Seppi K, Behnke S, et al. Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. A 37-Month 3‑Center Study of 1847 Older Persons. Arch Neurol. 2011 Jul;68(7):932–7
- Berg D, Weishaupt A, Francis MJ, Miura N, Yang XL, Goodyer I, Naumann M, Koltzenburg M, Reiners K, Becker G.Changes of Copper Transporting Proteins and Ceruloplasmin in the Lentiform Nuclei in Primary Adult-Onset Dystonia. Ann Neurol. 2000;47:827–30.
- Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology. 1999;53:1026–31.